津药药业股份有限公司 第九届董事会第二十四次会议决议公告

Core Viewpoint - Tianjin Pharmaceutical Industry Co., Ltd. has acknowledged the regulatory issues raised by the Tianjin Securities Regulatory Bureau and has committed to implementing a comprehensive rectification plan to address these concerns and enhance internal controls and compliance awareness [5][15]. Group 1: Meeting and Decision - The 24th meeting of the 9th Board of Directors was held on February 26, 2026, via telecommunication, with all 9 directors participating [1][3]. - The board unanimously approved the rectification report in response to the Tianjin Securities Regulatory Bureau's corrective measures [1][3]. Group 2: Rectification Requirements - The company aims to strictly adhere to relevant regulations, including the "Guidelines for the Governance of Listed Companies" and internal control application guidelines, ensuring thorough investigation and long-term management of identified issues [5][6]. - The rectification goals include resolving issues related to contract management, timely identification of R&D project termination risks, and improving internal control systems [6][15]. Group 3: Main Issues and Rectification Measures - Identified issues include non-standard contract management and delays in recognizing R&D project termination risks, leading to slow recovery of advance payments [7][10]. - Specific rectification measures include revising contract templates to ensure clarity and compliance, enhancing the contract review process, and establishing a risk management mechanism for R&D projects [8][11]. Group 4: Continuous Rectification Plan - The company has developed a continuous rectification plan to reinforce compliance education, enhance internal control systems, and optimize fund management processes [13][14]. - Ongoing training and supervision will be implemented to ensure adherence to regulations and improve governance standards [13][14]. Group 5: Commitment to Rectification - The board and management have expressed a strong commitment to addressing the issues highlighted by the regulatory authority and ensuring that all rectification measures are completed on time and effectively [15].